Finance

Results: 31117-31128 of 36716

Parse Biosciences Acquires Biomage

ExaGrid Announces New High Density 2U Product Line for Rack Space Efficiency

PR Newswire associated0

Agepha Pharma and Caristo Diagnostics Team Up to Fight Coronary Inflammation

PR Newswire associated0

FIRST PATIENTS ENROLLED IN THE GORE VBX FORWARD CLINICAL STUDY

PR Newswire associated0

Unchained Labs has the inside track on Lentivirus RNA detection, launches new Leprechaun application!

PR Newswire associated0

Epitomee® Announces Successful Completion of Pivotal Clinical Trial for Innovative Weight Loss Capsule

U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

KBI Biopharma, Inc. and Argonaut Manufacturing Services, Inc. Forge Strategic Alliance to Support Global Biopharmaceutical Companies with Integrated Drug Substance and Drug Product Solutions

KAYAK reveals when to book flights for popular summer holidays

Single Use Support continues to grow, expanding its team by 40%

On January 11th, trailblazing medical technology company Xenco Medical unveiled its convergent technology bridging Digital Health and Biomaterials by showcasing its TrabeculeX Continuum™ at the 2024 Consumer Electronics Show in Las Vegas, Nevada. Comprising the TrabeculeX Bioactive Matrix™ and the TrabeculeX Recovery App™, the TrabeculeX Continuum is the first technology-enabled bridge between orthobiologics and digital health, unifying a patient’s biomaterial implantation and postoperative journey. (Graphic: Business Wire)

Xenco Medical Unveils the TrabeculeX Continuum, a Breakthrough Convergence of Digital Health and Biomaterials, at CES 2024 in Las Vegas, the World’s Largest Technology Conference

Morgan Stanley Fourth Quarter and Full Year 2023 Earnings Results